These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29685715)

  • 1. A Small Change Can Make a Big Difference: A Lesson from Evolocumab.
    Mirzaee S; Thein PM; Wong D; Nasis A
    Heart Lung Circ; 2019 Mar; 28(3):e21-e22. PubMed ID: 29685715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atopic Dermatitis-Like Rash During Evolocumab Treatment of Familial Hypercholesterolemia.
    Kanda N; Okajima F
    J Nippon Med Sch; 2019; 86(3):187-190. PubMed ID: 31292332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
    El Khoury P; Elbitar S; Ghaleb Y; Khalil YA; Varret M; Boileau C; Abifadel M
    Curr Atheroscler Rep; 2017 Oct; 19(12):49. PubMed ID: 29038906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.
    Shirahama R; Ono T; Nagamatsu S; Sueta D; Takashio S; Chitose T; Fujisue K; Sakamoto K; Yamamoto E; Izumiya Y; Kaikita K; Hokimoto S; Hori M; Harada-Shiba M; Kajiwara I; Ogawa H; Tsujita K
    Intern Med; 2018; 57(24):3551-3557. PubMed ID: 30555118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
    Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibitor therapy in homozygous familial defective apolipoprotein B-100 due to APOB R3500Q: A case report.
    Andersen L; Davis T; Testa H; Andersen RL
    J Clin Lipidol; 2017; 11(6):1471-1474. PubMed ID: 28988723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A keen eye for risk.
    Ford TJ; Rocchiccioli P
    BMJ; 2018 Feb; 360():j5884. PubMed ID: 29419393
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
    Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
    J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM; Stefanutti C; Sniderman A; Watts GF
    Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
    Thiery J; Burkhardt R
    Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases.
    Lankin VZ; Tikhaze AK; Viigimaa M; Chazova IЕ
    Ter Arkh; 2018 Sep; 90(9):27-30. PubMed ID: 30701731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.